key: cord-1007035-feplqli2
authors: Amar, Jacques; Touront, Nicolas; Ciron, Antoine M.; Pendaries, Caroline
title: Interactions between hypertension and inflammatory tone and the effect on blood pressure and outcomes in patients with COVID‐19
date: 2021-01-24
journal: J Clin Hypertens (Greenwich)
DOI: 10.1111/jch.14137
sha: 0093d3902d3a78330f0613b091af728d2a5978bb
doc_id: 1007035
cord_uid: feplqli2

Arterial hypertension represented one of the most common comorbidities in patients with COVID‐19. However, the impact of hypertension on outcome in COVID‐19 patients is not clear. Close connections between inflammation and blood pressure (BP) have been described, and inflammation plays a key role in the outcome for patients with COVID‐19. Whether hypertension impairs the relationship between inflammation, BP, and outcomes in this context is not known. The aim of this study was to examine the effects of the interactions between inflammation and hypertension status on BP and clinical outcome in patients hospitalized with COVID‐19. We designed a retrospective study in 129 patients hospitalized with COVID‐19 at Toulouse University Hospital. The hospital outcome was admission to the intensive care unit or death. The inflammatory markers were blood C‐reactive protein level (CRP), neutrophil to lymphocyte, and platelet to lymphocyte ratios. We identified strong correlations between CRP (P < .01) and the other inflammatory markers recorded on admission (P < .001) with mean BP within 3 days after admission in normotensive patients, whereas these correlations were absent in patients with hypertension. Also, we observed after multivariate adjustment (P < .05) that CRP level predicted a worse prognosis in hypertensive patients (relative risk 2.52; 95% confidence intervals [1.03‐ 6.17]; P = .04), whereas CRP was not predictive of outcome in patients without hypertension. In conclusion, the study revealed that in COVID‐19 patients, hypertension impairs the relationship between inflammation and BP and interacts with inflammation to affect prognosis. These findings provide insights that could explain the relationship between hypertension and outcomes in COVID‐19 patients.

COVID-19, especially in patients 70 years and older in some [2] [3] [4] [5] but not all studies. [6] [7] [8] Thus, to date, the determinants of the prognosis for hypertensive patients with COVID-19 are not fully known.

Pneumonia and acute respiratory distress syndrome are complications frequently encountered in hospitalized patients with COVID- 19 . They require admission to intensive care and can result in death.

COVID-19-induced acute respiratory distress syndrome is caused by an overproduction of early response pro-inflammatory cytokines which in turn leads to what has been described as a cytokine storm, resulting in an increased risk of cardiovascular collapse. 9, 10 The impact of inflammation on blood pressure has been widely described in the literature. Observational and genetic analyses demonstrate a concordant, positive, and potentially causal relationship between inflammation and the immune system that affects systolic, diastolic, and pulse pressure. [11] [12] [13] Whether hypertension impairs the relationship between inflammation and blood pressure in the context of COVID-19 is not known. The aim of this study was to investigate the effects of interactions between inflammatory markers and hypertension status on blood pressure and hospital outcome in patients hospitalized with COVID-19.

We designed a retrospective study. All patients admitted to Toulouse University Hospital with COVID-19 during the period March 2020-April 2020, except patients admitted directly to an intensive care unit, were considered eligible. Patients were included according to the following criteria 1 : adults (over 18 years old) and laboratory confirmation of COVID-19 by real-time PCR, and /or chest computed tomography scan findings that meet the requirements for the diagnosis of COVID-19. Patients admitted directly to an intensive care unit were excluded. Demographic and biological data at inclusion were recorded. Hypertension was defined as the self-report of hypertension. As of admission, blood pressure was recorded five times a day, every day. Average daily blood pressure was taken into account. The first three days of the registration period were analyzed in the study. Inflammation markers were represented by blood C-reactive protein (CRP) concentration, platelet to lymphocyte ratio (PLR), and neutrophil to lymphocyte ratio (NLR). Computed tomography was used to quantify COVID-19 pneumonia. Each of the lung lobes was assessed using a scoring system. An overall score was obtained by adding up the five lobe scores, and the severity of lung involvement on CT scan was classified accordingly: absence or minimal (<10%), mild to moderate (10-50%), and severe (>50%). Admission to an intensive care unit or death during hospitalization defined the hospital outcome.

Continuous variables were recorded as means ± standard deviations, and categorical variables as percentages. We used the chi-square test for categorical variables and Student's t-test or the Wilcoxon test for continuous variables as appropriate, according to the skewness of the distribution as assessed by the Kolmogorov-Smirnov test. Logistic regression analysis was used to identify the independent predictors of the hospital outcome. The resulting values were expressed as hazard ratios, and a 95 percent confidence interval (p<0.05) was considered statistically significant. We used Spearman's rank-order correlation to analyze the correlation between blood pressure and inflammatory markers. Because of the large number of correlations, p<0.01 was considered statistically significant in this set of correlation analyses. The inflammatory markers found to be predictive of BP after admission were then entered in a multivariate linear regression model for age and gender. Statistical analyses were performed using SAS software (version 9.4 for Windows).

Data for 129 patients, 50 of whom were hypertensive, were analyzed (Table 1) . Patients with hypertension were older, had a lower estimated glomerular filtration rate, and higher pulse pressures.

Also, type 2 diabetes and treated dyslipidemia were more common in hypertensive patients compared to normotensive patients.

The hospital outcome occurred in 36.00 % of patients in the hypertensive group and in 26.58% of patients in the normotensive group (P = .26). On admission, the level of inflammatory markers and the severity of pneumonia as assessed by CT scan were not significantly different according to hypertension status. It is important to note that the level of inflammation on admission was highly correlated to blood pressure within three days after admission for normotensive patients while no significant correlation was observed in patients with hypertension ( Table 2 ). In the normotensive group, C-reactive protein was a strong predictor of systolic blood pressure, mean blood pressure, and pulse pressure within 3 days after admission, whereas PLR and NLR predicted systolic blood pressure and pulse pressure within 2 days after admission.

To illustrate this finding, the scatterplot between C-reactive protein as logarithm on admission and mean blood pressure at J3 in normotensive patients is shown in Figure 1 . In the multiple linear regression analysis, after adjustment for age, gender, diabetes, asthma, and body mass index, CRP predicted systolic and mean BP at day 3 and pulse pressure at day 2, NLR predicted SBP and PP at day 2, and PLR predicted PP at day 2 in normotensive patients, whereas no significant association was observed in patients with hypertension (Table 3) . Also, it is interesting to note that hypertensive patients who had a poor hospital outcome were more likely 

Arterial hypertension represented one of the most common comorbidities in patients with COVID-19. 14 However, the impact of hypertension on outcome and particularly on mortality in COVID-19

patients is not clear. The current study can help clarify this issue.

The main findings of this study were the interactions between inflammatory markers and hypertension status at admission, and the effect on both the blood pressure within 3 days and the hospital TA B L E 2 Correlation (Spearman's test) between inflammatory markers and blood pressure in the population as a whole, then in normotensive patients and in hypertensive patients on its own shown that endothelial function via the production of nitric oxide regulates aortic stiffness, a major determinant of blood pressure. 15 Furthermore, an observational population-based study has linked innate immunity and aortic stiffness. 16 A randomized trial also reported that an acute immune response against a pathogen increases aortic stiffness, a major determinant of systolic blood pressure. 17 In addition, similar findings to our data were reported in a population-based study indicating that blood CRP level predicts the augmentation index, which is closely related to microvascular resistance and consequently, with mean blood pressure. 18 From a mechanistic point of view, it has been demonstrated that this relationship between blood pressure and CRP is not mediated by atherosclerosis. 19 Several mechanisms by which inflammation and the immune system control blood pressure have been identified. [20] [21] [22] [23] Therefore, in the context of COVID-19, our observation of a strong and positive association between the level of various inflammatory markers at the time of hospital admission and blood pressure within 3 days in normotensive patients is in keeping with this body of evidence. It is important to note that these relationships were absent in patients with hypertension, in whom blood pressure appeared to be unresponsive to inflammatory tone. The mechanism of this interaction between hypertension status, inflammatory tone, and blood pressure cannot be elucidated in the context of this observational study. It is worth mentioning, however, that such an interaction has already been observed in animal models, 24 and it has been shown that spontaneously hypertensive rats have an attenuated inflammatory response to bacterial lipopolysaccharide. It can be hypothesized that hypertension-induced endothelial dysfunction 25,26 plays a role in the blunted effect of inflammation on blood pressure and ultimately on the prognosis of hypertensive patients with COVID-19. Interestingly, it has already been suggested that pre-existing endothelial dysfunction in patients with hypertension, diabetes, and obesity or aging, combined with vascular damage induced by SARS-CoV-2 could contribute to severe morbidity and mortality. 27 Indeed, evidence shows that SARS-CoV-2 has induced endothelial dysfunction or damage. Hence, it has been shown that endothelial involvement is associated with microvascular thrombi and prothrombotic state in patients with COVID-19. 28 The current study revealed that a high level of infection-induced inflammation at the time of admission predicts a poor prognosis in patients with hypertension. Patients with chronic hypertension usually need higher mean blood pressure levels than normotensive patients to achieve and maintain adequate perfusion pressure to the vital organs. 33 Therefore, mean blood pressure goals for these patients may need to be adapted 34 in the context of shock. In a prospective study, it was noted that a high target for mean arterial pressure was associated with improved microcirculation in septic shock patients with previous hypertension. 35 Moreover, the effect of such interaction between hypertension status and blood pressure on the prognosis in septic shock has been observed in humans 36 : In a randomized, stratified, open-label trial in patients with septic shock aimed at determining the optimal BP target according to hypertension status, the authors showed that among patients with chronic hypertension, those in the high-target group required less renal-replacement therapy than those in the low-target group.

Therefore, the lack of increase in BP in response to acute inflammation observed here in patients with previous hypertension may help to explain the prognosis of hypertensive patients with COVID-19.

A limitation of the study was due to limited availability of biomarkers of inflammation because of the retrospective design of the study. These biomarkers are needed to explore the interaction between inflammatory tone and hypertension status on blood pressure and outcomes.

Certainly, it would be of interest to analyze the impact of inflammation on blood pressure using biomarkers such as soluble CD14, von

Willebrand factor, and interleukin-6 to disentangle the biological pathway responsible for the interaction. Importantly, we analyzed all patients admitted to our hospital for infection with SARS-CoV-2 during the period March 2020-April 2020, except patients admitted directly to an intensive care unit, so there is no selection bias. Furthermore, all data required for analyzing the interaction between CRP and hypertension status on blood pressure and the prognosis were rigorously obtained in the context of patients hospitalized for SARS-CoV-2 infection.

Thus, the study results were based on high-quality data.

This study provides evidence of interactions between inflammatory tone and hypertension status at the time of hospital admission of patients with COVID-19 that affect both blood pressure and patient outcome. These findings provide insights into the prognosis of hypertensive patients with COVID-19. Also, these results have the potential to serve physicians by providing new information about inflammation influences on blood pressure regulation according to hypertension status.

We thank the participating patients, as well as the caregivers.

None.

Jacques Amar conceived the study, analyzed the data, and drafted the first version of the paper. Nicolas Touron conceived the study and collected the data. Antoine Ciron collected the data and was involved in writing the manuscript. Caroline Pendaries conceived the study, collected the data, and was involved in writing the manuscript. 

World Health Organization (WHO)

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Factors associated with COVID-19-related death using OpenSAFELY

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Hospitalization and Mortality among Black Patients and White Patients with Covid-19

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study

Age and Multimorbidity Predict Death Among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension

HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression

COVID-19 and cardiovascular consequences: Is the endothelial dysfunction the hardest challenge?

Relations of inflammatory biomarkers and common genetic variants with arterial stiffness and wave reflection

Multiple biomarkers and the risk of incident hypertension

White Blood Cells and Blood Pressure: A Mendelian Randomization Study

COVID-19 and arterial hypertension: Hypothesis or evidence?

Ex vivo aortic stiffness in mice with different eNOS activity

Soluble CD14 and aortic stiffness in a population-based study

Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals

An analysis of prospective risk factors for aortic stiffness in men: 20-year follow-up from the Caerphilly prospective study

Relationship between C reactive protein and pulse pressure is not mediated by atherosclerosis or aortic stiffness

Singlet molecular oxygen regulates vascular tone and blood pressure in inflammation

Kynurenine is an endothelium-derived relaxing factor produced during inflammation

Salt-responsive gut commensal modulates TH17 axis and disease

Essential roles of S-nitrosothiols in vascular homeostasis and endotoxic shock

Resistance to endotoxin shock in spontaneously hypertensive rats

Endothelial dysfunction and subsequent decline in glomerular filtration rate in hypertensive patients

The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators

COVID-19, Renin-Angiotensin System and Endothelial Dysfunction

Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence

The cytokine storm of COVID-19: a spotlight on prevention and protection

miR-98 Regulates TMPRSS2 Expression in Human Endothelial Cells: Key Implications for COVID-19

Endothelial cell infection and endotheliitis in COVID-19

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Textbook of medical physiology

Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock

A high mean arterial pressure target is associated with improved microcirculation in septic shock patients with previous hypertension: a prospective open label study

High versus low blood-pressure target in patients with septic shock

Interactions between hypertension and inflammatory tone and the effect on blood pressure and outcomes in patients with COVID-19